Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Profit After Tax (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Profit After Tax for 13 consecutive years, with -$71.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Profit After Tax rose 8.44% to -$71.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$391.0 million, a 5.06% decrease, with the full-year FY2025 number at -$391.0 million, down 5.06% from a year prior.
  • Profit After Tax was -$71.9 million for Q4 2025 at Iovance Biotherapeutics, up from -$91.3 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$71.9 million in Q4 2025 to a low of -$116.4 million in Q4 2023.
  • A 3-year average of -$100.6 million and a median of -$106.9 million in 2023 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: soared 32.5% in 2024, then dropped 14.99% in 2025.
  • Iovance Biotherapeutics' Profit After Tax stood at -$116.4 million in 2023, then skyrocketed by 32.5% to -$78.6 million in 2024, then increased by 8.44% to -$71.9 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Profit After Tax are -$71.9 million (Q4 2025), -$91.3 million (Q3 2025), and -$111.7 million (Q2 2025).